Browse Articles

Analysis of complement system gene expression and outcome across the subtypes of glioma

Mudda et al. | May 17, 2023

Analysis of complement system gene expression and outcome across the subtypes of glioma
Image credit: National Cancer Institute

Here the authors sought to better understand glioma, cancer that occurs in the glial cells of the brain with gene expression profile analysis. They considered the expression of complement system genes across the transcriptional and IDH-mutational subtypes of low-grade glioma and glioblastoma. Based on their results of their differential gene expression analysis, they found that outcomes vary across different glioma subtypes, with evidence suggesting that categorization of the transcriptional subtypes could help inform treatment by providing an expectation for treatment responses.

Read More...

3D Printed Polymer Scaffolds for Bone Tissue Regeneration

Jayatissa et al. | Apr 26, 2019

3D Printed Polymer Scaffolds for Bone Tissue Regeneration

Scientists are always on the quest to improve the body's healing abilities and broken bones are no exception. In this article, the authors investigate properties of 3D-printed biocompatible polymers used to improve bone healing. With such efforts, we can hope to, one day, improve bone scaffolding materials in ways that make the natural healing processes more efficient, reducing the time needed for recovery from bone fractures.

Read More...

Stereolithography 3D-printed stents with silica and zirconia nanoparticle reinforcement for intracranial aneurysm treatment

Panda et al. | Oct 12, 2026

Stereolithography 3D-printed stents with silica and zirconia nanoparticle reinforcement for intracranial aneurysm treatment
Image credit: Panda, Jeong, and Srinivasan

This manuscript focuses on improving the mechanical strength and radiopacity of SLA 3D-printed stent materials by incorporating nanoparticles for their application in flow-diverting stents (FDSs) used to treat aneurysms. The authors used biocompatible, bioresorbable resin formulations with varying concentrations of silica and zirconium to enhance tensile strength and radiopacity, respectively. The authors employed SEM to confirm the incorporation of nanoparticles, and CT imaging was used to assess the effect of zirconium-infused FDSs.

Read More...

Modular mimics of neuroactive alkaloids - design, synthesis, and cholinesterase inhibitory activity of rivastigmine analogs

Yu et al. | Sep 12, 2022

Modular mimics of neuroactive alkaloids - design, synthesis, and cholinesterase inhibitory activity of rivastigmine analogs

Naturally occurring neuroactive alkaloids are often studied for their potential to treat Neurological diseases. This team of students study Rivastigmine, a potent cholinesterase inhibitor that is a synthetic analog of physostigmine, which comes from the Calabar bean plant Physostigma venenosum. By comparing the effects of optimized synthetic analogs to the naturally occurring alkaloid, they determine the most favorable analog for inhibition of acetylcholinesterase (AChE), the enzyme that breaks down the neurotransmitter acetylcholine (ACh) to terminate neuronal transmission and signaling between synapses.

Read More...

Evaluating Biomarkers and Treatments for Acute Kidney Injury in a Zebrafish Model

Mathew et al. | Aug 11, 2019

Evaluating Biomarkers and Treatments for Acute Kidney Injury in a Zebrafish Model

Coronary Artery Disease (CAD) is the leading cause of death in the United States, and 81% of Acute Kidney Injury (AKI) patients in the renal fibrosis stage later develop CAD. In this study, Mathew and Joykutty aimed to create a cost-effective strategy to treat AKI and thus prevent CAD using a model of the zebrafish, Danio rerio. They first tested whether AKI is induced in Danio rerio upon exposure to environmental toxins, then evaluated nitrotyrosine as an early biomarker for toxin-induced AKI. Finally, they evaluated 4 treatments of renal fibrosis, the last stage of AKI, and found that the compound SB431542 was the most effective treatment (reduced fibrosis by 99.97%). Their approach to treating AKI patients, and potentially prevent CAD, is economically feasible for translation into the clinic in both developing and developed countries.

Read More...

Multi-omic analysis identifies mitochondrial dysfunction as a key feature of hypertrophic cardiomyopathy

Velu et al. | Sep 26, 2026

Multi-omic analysis identifies mitochondrial dysfunction as a key feature of hypertrophic cardiomyopathy

This study used multi-omic analysis to investigate gene expression and DNA methylation patterns associated with hypertrophic cardiomyopathy (HCM). The researchers found significant downregulation of mitochondrial and energy-related pathways, highlighting mitochondrial dysfunction—particularly altered PINK1 expression—as a potential contributor and therapeutic target in HCM.

Read More...